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Objective: We previously validated a gene expression score (GES) based on age, sex and peripheral blood
cell expression levels of 23 genes measured by quantitative real-time PCR (qRT-PCR) for diagnosis of
obstructive coronary artery disease (CAD) (50% luminal diameter stenosis). In this study we sought to
determine the association between the GES and coronary arterial Plaque Burden and Stenosis by CT-
angiography.
Methods: A total of 610 patients (mean age: 57  11; 50% male) from the PREDICT and COMPASS studies
from 59 centers were analyzed. Coronary artery calcium (CAC) scoring, CT angiography (CTA)-based
plaque and stenosis and GES measurements were performed. CAC was expressed as Agatston score and
CTA evaluated for stenosis severity: 0. None; 1. Minimal, 2. Mild, 3. Moderate, 4. Severe and 5. Occluded.
Correlation analysis, one-way analysis of variance (ANOVA) and receiver operating characteristics (ROC)
analyses were performed.
Results: GESwas signiﬁcantlyassociatedwithplaqueburdenbyCAC (r¼0.50; p<0.001) andCTA (segment
involvement score index: r ¼ 0.37, p < 0.001); a low score (15) had sensitivity of 0.71 and a high score
(28) a speciﬁcity of 0.97 for the prediction of zero vs. non-zero CAC. Increasing GES was associatedwith a
greater degree of categorical stenosis by ANOVA (p < 0.001); GES signiﬁcantly correlated with maximum
luminal stenosis (r¼ 0.41; p< 0.01) and segment stenosis score index (r¼ 0.38; p< 0.01). A low score had
sensitivity of 0.90 and a high score a speciﬁcity of 0.87 for 70% stenosis.
Conclusions: A previously validated GES is signiﬁcantly associated with Plaque Burden and Stenosis
by CT.
Clinical trial registration.: (PREDICT [NCT00500617] and COMPASS [NCT01117506]),www.clinicaltrials.gov
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.: þ1 650 319 7048.
, srbchem52@gmail.com
r Ltd. Open access under CC BY-NC-SA1. Introduction
Atherosclerosis is initiated by the retention of atherogenic li-
poprotein particles in the susceptible vessel wall, triggering an
initially protective, and later a maladaptive inﬂammatory response
[1]. Further steps, occurring over decades, include macrophage and
foam cell apoptosis, the development of a necrotic core, smooth-
muscle cell proliferation, collagen deposition and calciﬁcation,
which is thought to be a response to intra-plaque hemorrhage [2].
Progression of coronary artery disease via a dynamic process
of atherosclerotic plaque accumulation, erosion and rupture license.
Table 1
Demographic Characteristics of the Study Population as well as the Individual
PREDICT and COMPASS Cohorts.a
COMPASS (N ¼ 394) PREDICT (N ¼ 216) All (N ¼ 610)
Males 198 (50.3%) 108 (50%) 306 (50.2%)
Age 55  10 59  11 57  11
Caucasian 351 (89.1%) 196 (90.7%) 547 (89.7%)
Systolic BP 129  17 129  18 129  17
Dyslipidemia 215 (54.6%) 145 (67.1%) 360 (59%)
Chest pain status
Asymp 1 (0.3%) 61 (28.2%) 62 (10.2%)
Atypical 68 (17.3%) 40 (18.5%) 108 (17.7%)
NonAnginal 304 (77.2%) 91 (42.1%) 395 (64.8%)
Typical 21 (5.3%) 24 (11.1%) 45 (7.4%)
BMI 30  6 30  6 30  6
Smoking status
Current 60 (15.2%) 17 (7.9%) 77 (12.6%)
Former 113 (28.7%) 71 (32.9%) 184 (30.2%)
Never 221 (56.1%) 128 (59.3%) 349 (57.2%)
Aspirin use 188 (47.7%) 125 (57.9%) 313 (51.3%)
Statin use 179 (45.4%) 117 (54.2%) 296 (48.5%)
Beta-blocker use 79 (20.1%) 57 (26.4%) 136 (22.3%)
a The values for the demographic, clinical, and medication parameters for the
individual PREDICT and COMPASS cohorts and the entire population of N ¼ 610 are
shown.
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angina, and perhapsmyocardial infarction [3]. This process involves
a role for many circulating cell types from both the innate and
adaptive arms of the immune system [4,5].Fig. 1. Correlation analyses of the GES with Calcium Score and measures of Plaque Burden a
[B], SSSi [C] and maximum percent stenosis [D] are shown with PREDICT patient values (
correlation in Black, with jiggering of identical values for illustrative purposes. The overall c
cohort speciﬁc correlations were 0.45, 0.30, 0.27, and 0.30 in PREDICT, and 0.52, 0.43, 0.44, a
MPI (p ¼ 0.028, and 0.017, respectively).Using a series of microarray and qRT-PCR studies we ﬁrst iden-
tiﬁed genes whose expression correlated with the extent of CAD [6]
and then developed and validated an algorithm for obstructive CAD
likelihood based on age, sex, and peripheral blood cell expression
levels of 23 genes [7e9]. The majority of these genes are predomi-
nantly expressed in cells of the innate immune system, partially
reﬂecting increased neutrophil counts in CAD patients and cardio-
vascular events [10], as well as additional roles in atherosclerosis
such as apoptosis and response to oxidative damage [11,12].
Clinical evaluation of CAD patients is based on the assessment of
CAD likelihood using traditional risk factors. Patients with inter-
mediate probability are typically evaluated by functional non-
invasive testing to detect ischemia, while those with high-
likelihood are referred for invasive coronary angiography to
conﬁrm luminal stenosis [13], or more recently, by contrast-
enhanced coronary computed tomography angiography (CTA)
[14]. Calciﬁed plaque can be quantiﬁed by non-contrast-enhanced
coronary artery calcium (CAC) scanning and overall coronary pla-
que can be directly visualized and quantiﬁed by CTA [15].
The gene expression score (GES) was developed to discriminate
obstructive CAD likelihood, but was also shown to correlate with
luminal stenosis as measured by quantitative coronary angiography
(QCA) [8]. This observation was further supported by a small study
of the GES with intra-vascular ultrasound results [16]. However,
whether the GES is also associated with plaque burden and luminal
stenosis by CAC and CTA is unknown. Therefore, we tested this
hypothesis in two clinical studies where patients were referred for
CTA or myocardial perfusion imaging.nd Stenosis by CT. Scatter plots illustrating the correlation of the GES with CAC [A], SISi
red triangles) and correlation in Red and COMPASS patient values (black circles) and
orrelations were 0.50, 0.37, 0.38, and 0.41, respectively for CAC, SISi, SSSi, and MPS; the
nd 0.47, in COMPASS. The correlation differences reached signiﬁcance only for SSSi and
S. Voros et al. / Atherosclerosis 233 (2014) 284e2902862. Methods
2.1. Study population
This study is based on 610 patients who underwent CAC, CTA and
GES in thePREDICT (NCT#00500617)andCOMPASS (NCT#01117506)
GES validation studies in patients referred for invasive or CT-
angiography and myocardial perfusion imaging, respectively [8,9].
Therewere 237 patientswho had coronary CTA in the PREDICTstudy,
of whom 216 (91%) with interpretable images were included in the
ﬁnal cohort analysis. This study enrolled symptomatic patients or
high-risk asymptomatic subjects clinically referred for invasive cor-
onary angiography or CTA, with no previously known history of CAD
or revascularization. Key exclusion criteria included acute coronary
syndromes, severe non-coronary cardiovascular disease, diabetes,
systemic infectious or inﬂammatory diseases and the use of immu-
nosuppressant or chemotherapeutic agents.
From the COMPASS study population of 431 patients, 33 were
referred directly for ICA, and 4 had CT-angiographic images that
were not suitable for core laboratory analysis, yielding 394 (91%) in
the ﬁnal analysis cohort. The COMPASS study enrolled symptomatic
patients with no history of MI or revascularization who were
clinically referred for myocardial perfusion imaging [9], with
similar exclusion criteria as for PREDICT.
Both study protocols and the informed consent forms were
approved by applicable institutional review boards and all patients
provided written informed consent.
2.2. CAC image acquisition and quantiﬁcation
A 64-slice CT scanner system or higher was required for study
site participation. CAC scans were obtained using local institutional
protocols, with tube potential of 120 kV. Scan length, tube current,
scan mode and EKG-modulation, collimation (when appropriate),
inter-slice gap and reconstruction slice thickness were determined
by local institutional protocols. Quantiﬁcation of CAC was per-
formed by each site and expressed as the Agatston score [17].
2.3. CTA image acquisition and image analysis
Given the diversity of image acquisition parameters and stra-
tegies for coronary CTA, image acquisition was performed based onTable 2
Diagnostic Accuracy of gene expression score for the diagnosis of plaque burden and lum
Value GESa threshold GES AUCb DeFc AUC
Plaque burden
CAC > 0 “Optimal”e (18) 0.75 (0.71e0.79) 0.65 (0.61e0
Low (15)
High (28)
CAC  400 “Optimal” (22) 0.75 (0.68e0.82) 0.61 (0.53e0
Low (15)
High (28)
SISi > 0 “Optimal” (14) 0.72 (0.68e0.76) 0.63 (0.59e0
Low (15)
High (28)
Luminal stenosis
50% “Optimal” (19) 0.75 (0.70e0.80) 0.65 (0.59e0
Low (15)
High (28)
70% “Optimal” (19) 0.75 (0.67e0.83) 0.63 (0.53e0
Low (15)
High (28)
a GES is gene expression score which is reported on a 1-40 scale.
b AUC is area under the curve in receiver-operating characteristics (ROC) analysis; val
c DeF is the DiamondeForrester classiﬁcation for obstructive CAD likelihood.
d ACCU is overall diagnostic accuracy.
e “Optimal” is the threshold which maximizes the sum of sensitivity and speciﬁcity folocal, institutional protocols. For image analysis, the coronary sys-
temwas evaluated based on amodiﬁed AHAmodel, as suggested by
the Society for Cardiovascular Computed Tomography [18]. Each of
the 17 segments was evaluated semi-quantitatively for the pres-
ence and composition of plaque (0. none; 1. calciﬁed; 2. non-
calciﬁed and 3. partially calciﬁed plaque) and for the degree of
luminal diameter stenosis (0. None; 1. Minimal [<25%], 2. Mild
[25e49%]; 3. Moderate [50e69%]; 4. Severe [70e99%] and 5.
Occluded [100%]). Each patient was categorized for the degree of
stenosis based on the most severe stenosis in any segment. In
PREDICT, two independent core laboratories performed all quali-
tative analyses and similarly, in COMPASS, two independent
readers interpreted all studies.
In addition to segmental analysis, we also calculated composite
scores that reﬂect overall plaque burden and the extent of stenotic
segments. Segment involvement score index (SISi) is the number of
segments with any plaque, regardless of composition and severity,
normalized to a possible range of 0e17 segments. Segment stenosis
score index (SSSi) is a sum of all individual segmental stenosis
scores across all segments, normalized to a possible range of 0e17
segments [19]. In addition, in the COMPASS patients, the degree of
stenosis was also measured by quantitative analysis using a pre-
viously validated method [15,20].
For the CTA parameters (maximum degree of stenosis, SISi,
and SSSi), each subject’s values were computed using the mean
of three interpretations: in PREDICT, the two independent core
lab qualitative interpretations and the clinical interpretation; in
COMPASS, the two independent core lab qualitative in-
terpretations and the core lab quantitative measurement. In
case of disagreement in qualitative interpretation between
readers, the quantitative measurement was used to resolve
disagreement.
2.4. Measurement of peripheral blood cell gene expression score
We utilized a previously validated qRT-PCR based peripheral
blood gene expression test run in a CLIA-certiﬁed laboratory (Cor-
us CAD; CardioDx, Inc; Palo Alto, CA) [7,8,21], which is comprised
of age, sex, and levels of 23 genes expressed in peripheral blood
cells, that have been associated with obstructive CAD. The test re-
ports a score of 1e40, with higher scores associated with higher
likelihood of obstructive CAD. Whole blood samples were collectedinal stenosis.
SENS SPEC NPV PPV ACCUd
.69) 0.62 0.73 0.65 0.69 0.68
0.71 0.62 0.68 0.65 0.66
0.26 0.97 0.57 0.89 0.61
.69) 0.70 0.74 0.95 0.21 0.72
0.84 0.49 0.97 0.14 0.66
0.41 0.88 0.94 0.26 0.65
.67) 0.73 0.58 0.69 0.64 0.66
0.70 0.61 0.67 0.64 0.65
0.25 0.95 0.56 0.84 0.60
.71) 0.76 0.61 0.94 0.25 0.69
0.84 0.51 0.95 0.23 0.67
0.40 0.90 0.90 0.40 0.65
.73) 0.84 0.58 0.99 0.10 0.71
0.90 0.48 0.99 0.08 0.69
0.45 0.87 0.97 0.16 0.66
ues in parentheses are the 95% conﬁdence limits.
r the parameters being compared.
Fig. 2. ROC Curves of the GES to Predict Measures of Plaque Burden and Stenosis by CT. Areas under the ROC curves indicate excellent diagnostic accuracy of the GES to predict
presence of plaque (non-zero CAC [A], CAC  400 [B], SISi > 0 [C]) and luminal stenosis (MPS  50% [D] and MPS  70% [E]). ROC: receiver operating characteristics; CAC; coronary
artery calcium; SISi: segment involvement score index; MPS: maximum percent stenosis.
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CTA, treated according to the manufacturer’s instructions, then
frozen at 20 C. RNA puriﬁcation, cDNA synthesis, and qRT-PCR
were performed as previously described with all PCR reactions
run in triplicate and median values used for score calculation
[7,8,21].2.5. Statistical analysis
Analyses were done in R Version 2.14.2 [22], and used the lm
function for linear regression, the aov function for ANOVA, and the
rcorr.cens function for ROC analysis. Continuous variables were
expressed as mean  SD or as median [inter-quartile range], as
Fig. 3. Categorical Analysis of Gene Expression Score as a Function of Increasing
Maximum Percent Stenosis. GES levels are shown in each of the qualitative categories
of maximum percent stenosis per patient, showing monotonically increasing GES
levels with increasing degree of stenosis, except for the occluded category which
represents only 2 patients. Percentage of patients in each category is indicated within
the black boxes over the bars, with 277, 101, 143, 58, 29, and 2 patients in categories 1e
5, respectively. There was a highly signiﬁcant correlation of the GES with stenosis
category by one-way ANOVA (p < 0.001). GES: gene expression score; ANOVA: analysis
of variance.
S. Voros et al. / Atherosclerosis 233 (2014) 284e290288appropriate based on the distribution. Continuous variables were
compared by t-test (2-tailed), and categorical variables using the
Chi-squared test.
2.5.1. Correlation analysis
Linear regression was used to assess correlation between GES
and SISi, SSSi, and CAC scores; CAC scores were log-transformed
given a skewed distribution. To assess association between GES
and CTA-derived stenosis as a categorical variable, we used one-
way analysis of variance (ANOVA).
2.5.2. Receiver operator characteristics (ROC) analysis
We used ROC analysis of the GES to predict the presence and
degree of CAC with two different dichotomous thresholds (CAC > 0
and CAC  400) and to assess the diagnostic characteristics of the
GES to predict any, 50% and 70% stenosis by CTA in both the com-
plete cohort and in a gender-speciﬁc manner. In addition, we
determined GES performance at pre-speciﬁed GES thresholds
(GES 15 for low and GES 28 for high score), as well as at optimal
GES thresholds based on the value where the sum of sensitivity and
speciﬁcity was maximized [9].
3. Results
3.1. General demographics
A total of 216/237 (91%) non-diabetic patients from PREDICT and
394/398 (99%) from COMPASS had interpretable CT images, CAC,
and GES, comprising the 610 patients in the ﬁnal analysis group for
whom general demographic characteristics are shown in Table 1. In
this overall cohort, average age and proportion of males wereTable 3
Gender speciﬁc ROC analysis of gene expression and DiamondeForrester scores associat
Parameter DeF AUC (male) GES AUC (ma
CAC > 0 0.67 (0.60e0.74) 0.73 (0.67e0.
50% stenosis 0.64 (0.57e0.71) 0.69 (0.62e0.
70% stenosis 0.61 (0.51e0.71) 0.72 (0.61e0.57  11 years and 50%, respectively. The prevalence of obstructive
disease (50% stenosis) was 16% and 13% in the PREDICT and
COMPASS subsets, respectively. PREDICT patients were older, with
more dyslipidemia and were prescribed more aspirin and statins
than the COMPASS patients.
3.2. Coronary artery calcium, plaque burden, and stenosis
The median CAC was 0.2 [0e83.8], with a range of 0e3213. A
zero CAC score was seen in 50% of patients; 56 patients (9.3%) had
CAC  400. Of the 610 patients in the CTA cohort, 277 (45.4%) had a
normal CTA. Average maximum percent diameter stenosis per pa-
tient in the population was 20.4  25.0. Based on their worst ste-
nosis, the percentage of patients with normal, minimal, mild,
moderate, severe stenosis and occluded segments were 45, 17, 23,
9.5, 4.7, and 0.3%, respectively. Average SISi and SSSi were 1.9  2.6
and 3.4  5.4, respectively.
3.3. Gene expression score and plaque burden
There was modest but signiﬁcant correlation between calciﬁed
plaque burden as measured by the Agatston score and the GES
(r¼ 0.50; p< 0.001), and between GES and SISi (r¼ 0.37; p< 0.001)
(Fig. 1A,B), with generally increased correlation in the COMPASS
compared to the PREDICT cohorts. ROC analysis-based area under
the curve (AUC) values, sensitivity, speciﬁcity, negative predictive
value (NPV), positive predictive value (PPV) and overall accuracy of
GES to predict CAC > 0, CAC  400 and SISi > 0 are shown in
Table 2; ROC curves are shown in Fig. 2.
3.4. GES and luminal stenosis
When stenosis severity was analyzed as a categorical variable,
there was signiﬁcant association between the GES and this
parameter as measured by CTA with increasing maximal stenosis
associated with increasingly higher GES (global p < 0.001) (Fig. 3).
There was also modest, signiﬁcant correlation between GES and
SSSi (r ¼ 0.38; p < 0.01) as well as GES and maximum percent
diameter stenosis as a continuous variable (r ¼ 0.41; p < 0.01)
(Fig. 1C,D and Table 2). AUC values, sensitivity, speciﬁcity, NPV, PPV
and accuracy of GES to predict 50% and70%maximum diameter
stenosis are shown in Table 2. In addition, the GES had higher
diagnostic accuracy than the DiamondeForrester classiﬁcation at
both 50% stenosis (AUC: 0.75 vs. 0.65; p ¼ 0.004) and 70% stenosis
(AUC: 0.75 vs. 0.63; p ¼ 0.029).
Gender-speciﬁc ROC analyses for CAC > 0 and 50% and 70%
stenosis are shown in Table 3. The GES had a higher point estimate
for the AUC than DiamondeForrester in both genders and across
the 3 parameters examined, although it only reached statistical
signiﬁcance for women in the CAC > 0 analysis.
4. Discussion
Our study evaluates the association between a previously vali-
dated composite gene expression score and Plaque Burden and
Stenosis evaluated by CAC and contrast-enhanced coronary CTion with CAC and CTA based luminal stenosis.
le) DeF AUC (female) GES AUC (female)
79) 0.55 (0.48e0.62) 0.71 (0.65e0.77)
76) 0.58 (0.44e0.72) 0.74 (0.64e0.84)
83) 0.54 (0.29e0.79) 0.76 (0.60e0.90)
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GES in a cohort of patients undergoing invasive X-ray coronary
angiography and validated it in an independent cohort of patients
with the same invasive x-ray coronary angiographic endpoint [8].
However, in the present study, we had the opportunity to validate
the same algorithm in an independent cohort of 610 patients who
underwent CAC and CTA to deﬁne coronary plaque burden and
luminal stenosis in the PREDICT and COMPASS clinical studies.
The current study has three important ﬁndings. First, we found
that the GES was associated with plaque burden as measured by
both CAC and CTA. Second; the GES was also associated with
luminal stenosis as measured by CTA, and was a stronger predictor
of stenosis, as compared to the DiamondeForrester clinical classi-
ﬁcation. Finally, the GES increased with increasing maximum
percent stenosis by CTA as seen previously with ICA.
The maladaptive inﬂammatory response characteristic of
atherosclerosis is mounted through the innate and adaptive arms
of the immune system with monocytic cell inﬁltration and differ-
entiation into macrophages and foam cells in the sub-endothelium
in the presence of excess lipid deposition, giving rise to increased
chemokine production [23]. This in turn may affect the distribution
of bone marrow progenitors resulting in an increase in myeloid
precursors and accelerating atherosclerosis as has recently been
reviewed [24,25]. A signiﬁcant correlation between neutrophil
counts and adverse cardiovascular events has been seen in mul-
tiple studies [10,26]. The gene expression score used in this study
contains several genes which are selectively expressed in the
myeloid lineage, such as S100A12 [27] and S100A8. Over-
expression of the former in a transgenic mouse model has also
been shown to be associated with increased arterial calciﬁcation
[28], which may explain part of the correlation of CAC with the
GES.
We found that the GES was associated with plaque burden, as
measured both by CAC and CTA. CAC as quantiﬁed by the Agatston
score has been validated extensively for the prediction of inter-
mediate and long-term hard clinical outcomes [29e31]. From a
clinical perspective, use of the Agatston score allows for the re-
classiﬁcation of 25% of patients compared to clinical factors alone
[31]. Patients with zero CAC have excellent long-term outcomes
[31], whereas patients with CAC over 400 have signiﬁcantly worse
prognosis [29]. In this context, the GES was signiﬁcantly associated
with CAC (r ¼ 0.50; p < 0.001), with an AUC of 0.75 for the pre-
diction of CAC ¼ 0. For a low score (15) the GES had sensitivity of
0.71, and for a high score (28), a speciﬁcity of 0.97, for the pre-
diction of a non-zero CAC.
Another key ﬁnding of our study is that progressively increasing
GES was associated with progressively increasing luminal stenosis
by CTA (Fig. 3). It has been shown in 23,854 patients in the
CONFIRM registry that survival gradually worsened with non-
obstructive (<50%) and obstructive (50%) CAD [30]. A similar
observation was found in a meta-analysis of over 7000 patients
[32]. In this context, for the prediction of 50% luminal stenosis,
AUC was 0.75; a low score (15) had a sensitivity of 0.84 and a high
score (28) had a speciﬁcity of 0.90; the speciﬁcity of a high score
for the prediction of 70% luminal stenosis was 0.87, illustrating
that the GES has high clinical accuracy for the diagnosis of signiﬁ-
cant obstructive CAD, similar to our ﬁndings based on invasive
angiography in the PREDICT study.
The clinical signiﬁcance of our ﬁndings is that as the GES is
associated with both plaque burden and luminal stenosis it might
be used prior to or in lieu of, non-invasive imaging techniques to
assess the presence of atherosclerosis and luminal stenosis. Since
the GES does not require ionizing radiation or contrast agents, it
may be preferred to imaging modalities that do in more vulnerable
populations.Our study has several limitations. First, the study population
was limited to non-diabetic patients who did not have known CAD
and were seen in the stable, out-patient setting. Second, we did not
examine the relative predictive value of GES, CAC and CTA for
clinical outcomes measures; this would have required a larger
sample size and longitudinal follow-up. We have previously shown
that in both the PREDICT and COMPASS studies that the GES is
correlated with a composite outcome of revascularization and
major adverse cardiovascular events [9,33]. Third, treatment of
patients with lipid-modifying medications and some anti-
inﬂammatory medications was not pre-speciﬁed, and treatment
may have signiﬁcant effects on global peripheral gene expression
patterns, although such effects did not appear to be major factors in
our original algorithm development and subsequent validation
work [7,9]. Fourth, the population studied was largely Caucasian,
and larger numbers of other ethnic groups need to be studied to
estimate the relationship of the GES performance to CT parameters
in those populations. Lastly, the relatively modest correlations of
the GES with measures of plaque burden may reﬂect atheroscle-
rotic disease in other vascular beds or a differential sensitivity of
peripheral blood gene expression changes to plaque composition.
5. Conclusions
In summary, in this study of 610 patients from the PREDICT and
COMPASS studies we found that a previously validated peripheral
blood-based GES based on age, gender, and expression levels of 23
genes is signiﬁcantly associated with plaque burden as assessed by
CAC and CTA and with luminal stenosis, as assessed by contrast-
enhanced CTA. The GES has good diagnostic accuracy for the detec-
tion of calciﬁed plaque burden, with a sensitivity of a low score of 0.71
andwith a speciﬁcity of a high score 0.97 for the prediction of zero vs.
non-zero CAC. In addition, a low score had a sensitivity and NPV of
0.84 and 0.95 for the prediction of 50% luminal stenosis, and a
sensitivityandNPVof0.90and0.99 for thepredictionof70% luminal
stenosis. The GES may provide an accurate, non-radiation-based
alternative for the diagnosis of signiﬁcant plaque burden and CAD.
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